Clinical Trial

Efficacy of Chatbot for Irritable Bowel Syndrome (IBS) Patients

Study acronym: IrBiS
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated February 20, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the efficacy of an automated chatbot system in improving quality of life, reducing depression and anxiety, and decreasing visceral sensitivity in patients with Irritable Bowel Syndrome. The main research question is: Is an automated chatbot as effective for patients with IBS as standard care? Participants will be asked to complete online surveys to assess quality of life, symptoms of depression and anxiety, and visceral sensitivity before and after the intervention.
Trial Details
NCT Number NCT06837064
Lead Sponsor Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
Collaborators: I.M. Sechenov First Moscow State Medical University
Conditions Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation, Irritable Bowel Syndrome - Diarrhoea, Irritable Bowel Syndrome - Mixed
Enrollment 54 participants
Start Date 2025-03
Primary Completion 2025-05 (estimated)
Study Completion 2025-08 (estimated)
Updated on ClinicalTrials.gov 2025-02-20